Becton, Dickinson and Company Q3 2026 Earnings Recap

BD's shares rose 3.6% post-earnings, driven by revenue growth above expectations and an upward revision to adjusted EPS guidance, signaling market approval of the company’s focused portfolio and operational execution.

Key Takeaways

• Revenue reached $5 billion, up 4.4% year-over-year on an FX-neutral basis, with over 90% of the portfolio delivering high single-digit growth.
• Adjusted operating margin expanded to 24.9%, reflecting improved mix and operational efficiency under the BD Excellence program.
• Adjusted EPS came in at $3.23, prompting a raised midpoint for full-year EPS guidance and updated revenue growth target toward the high end of low single digits.
• Broad-based growth was supported by double-digit expansion in biologic drug delivery, advanced patient monitoring, PureWick, and advanced tissue regeneration platforms.
• Commercial investments in key segments like Advanced Patient Monitoring and PureWick contributed to accelerating growth and share gains, particularly in the U.S. market.